Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.

Carola Riva, Paola Minetto, Giada Zecchetti, Stefano Nicoletta, Ylenia Azzanelli, Roberta Romei, Nicoletta Colombo, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2025-3402

Published: 2025

Journal Articles

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

Blood (2025) 146 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2025-3806

Published: 2025

Journal Articles

VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics

Livio Pagano, Alessandra Sperotto, Elisabetta Todisco, Roberto Lemoli, Massimo Breccia, Alessandro Rambaldi, Sara Galimberti, Saemi Park, Giovanna Dinelli, Rafaella Gentilella, Adriano Venditti

Blood (2025) 146 (Supplement 1): 5212.

https://doi.org/10.1182/blood-2025-5212

Published: 2025

Journal Articles

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial

Blood (2025) 146 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2025-3516

Published: 2025

Journal Articles

CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.

Fabio Guolo, Carola Riva, Enrico Carminati, Giada Zecchetti, Stefano Nicoletta, Roberta Romei, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Lemoli, Paola Minetto

Blood (2025) 146 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2025-1629

Published: 2025

Journal Articles

The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.

Paola Minetto, Carola Riva, Enrico Carminati, Giada Zecchetti, Francesco Puglisi, Clara Nurra, Michele Cea, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2025-1625

Published: 2025

Journal Articles

Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.

Blood (2025) 146 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2025-1623

Published: 2025

Journal Articles

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Elisabetta Todisco, Ivana Lotesoriere, Federico Lussana, Valentina Mancini, Federica Gigli, Cristina Papayannidis, Michela Rondoni, Felicetto Ferrara, Sara Mastaglio, Annalina Piccioni, Michelina Dargenio, Andrea Corbingi, Francesco Mannelli, Alessandro Cignetti, Patrizia Zappasodi, Maria Paola Martelli, Monia Lunghi, Luana Fianchi, Patrizia Chiusolo, Francesco Grimaldi, Federica Pilo, Carla Fili, Debora Capelli, Massimo Breccia, Monica Bocchia, Monica Fumagalli, Sara Galimberti, Luca Maurillo, Calogero Vetro, Alessandra Sperotto, Caterina Patti, Erika Borlenghi, Federica Lessi, Alessandro Isidori, Raffaele Palmieri, Caterina Alati, Samuele Gatani, Chiara Pessina, Paola Minetto, Carola Riva, Marco Frigeni, Nicola Stefano Fracchiolla, Carla Mazzone, Marco Cerrano, Massimo Bernardi, Michele Gottardi, Roberto Cairoli, Adriano Venditti, Livio Pagano, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2025-4608

Published: 2025

Journal Articles

Fludarabine, cytarabine and Idarubicin (FLAI-5) with or without Gemtuzumab Ozogamicin Is an Effective and Well Tolerated Regimen for Younger AML Patients: Real Life Data from a Single Center Register

Fabio Guolo, MD, Paola Minetto, MD, Giordana Pastori, MD, Livia Giannoni, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Francesco Trovato, MD, Marcella Bado, MD, Filippo Ballerini, MD, Marino Clavio, MD, Barbara Rebesco, MD, Maurizio Miglino, PhD, Andrea Bacigalupo, MD, Marco Gobbi, MD, Roberto Lemoli, MD

Blood (2014) 124 (21): 2266.

https://doi.org/10.1182/blood.V124.21.2266.2266

Published: 2014

Journal Articles

Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation

Livia Giannoni, MD, Fabio Guolo, MD, Paola Minetto, MD, Federica Galaverna, MD, Chiara Ghiggi, MD, Marino Clavio, MD, Samuele Bagnasco, MD, Carmen Di Grazia, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Daniele Avenoso, MD, Giordana Pastori, MD, Filippo Ballerini, MD, Annalisa Kunkl, PhD, Maurizio Miglino, PhD, Roberto Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2014) 124 (21): 1027.

https://doi.org/10.1182/blood.V124.21.1027.1027

Published: 2014

Journal Articles

Posaconazole for Primary Antifungal Prophylaxis in AML Patients: A Real Life Single Center Experience and a Comparison with the Historical Cohort

Paola Minetto, MD, Fabio Guolo, MD, Malgorzata Mikulska, MD, Giordana Pastori, MD, Livia Giannoni, MD, Elisa Furfaro, Franca Miletich, Valerio Del Bono, MD, Filippo Ballerini, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Roberto Lemoli, MD, Claudio Viscoli, MD, Marco Gobbi, MD

Blood (2014) 124 (21): 5255.

https://doi.org/10.1182/blood.V124.21.5255.5255

Published: 2014

Journal Articles

Combined Assessment of WT1 and BAALC Expression Levels Improves Risk Stratification in Myelodysplastic Syndromes

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Laura Mitscheunig, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Enrico De Astis, MD, Daniele Avenoso, MD, Livia Giannoni, MD, Giordana Pastori, MD, Lisette Del Corso, MD, Enrico Balleari, MD, Filippo Ballerini, MD, Roberto Lemoli, MD, Marco Gobbi, MD, Maurizio Miglino, PhD

Blood (2014) 124 (21): 5603.

https://doi.org/10.1182/blood.V124.21.5603.5603

Published: 2014

Journal Articles

How We Treat Chronic Myeloid Leukemia Patients During Daily Practice? Case Studies From The Real Life Experience Of Two Genoa Centers Of Hematology

Laura Mitscheunig, Micaela Bergamaschi, MD, Raffalla Grosso, Maurizio Miglino, PHD, Marino Clavio, MD, Filippo Ballerini, PHD, Letizia Canepa, MD, Riccardo Varaldo, Roberto Lemoli, Marco Gobbi, MD, Ivana Pierri, MD

Blood (2013) 122 (21): 5192.

https://doi.org/10.1182/blood.V122.21.5192.5192

Published: 2013

Journal Articles

Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors

Maria Rosaria Ricciardi, Valentina Salvestrini, Mattia Forcato, Roberto Licchetta, Simone Mirabilii, Lara Rossi, Matteo Allegretti, Martina Vincenzi, Simona Salati, Phd, Fausto Castagnetti, Gianantonio Rosti, Giuliana Alimena, Rossella Manfredini, PhD, Silvio Bicciato, PhD, Roberto Lemoli, Agostino Tafuri

Blood (2013) 122 (21): 2712.

https://doi.org/10.1182/blood.V122.21.2712.2712

Published: 2013

Journal Articles

Efficacy and Tolerability Of Frontline Oral Fludarabine and Cyclophosphamide Combination Therapy For Elderly Patients With Chronic B-Cell Lymphocytic Leukaemia and Low Grade Non Hodgkin Lymphoma

Micaela Bergamaschi, MD, Laura Mitscheunig, Fabio Guolo, MD, Anna Ghiso, Federica Galaverna, Maurizio Miglino, PHD, Marino Clavio, MD, Filippo Ballerini, PHD, Letizia Canepa, MD, Roberto Lemoli, Marco Gobbi, MD, Ivana Pierri, MD

Blood (2013) 122 (21): 5095.

https://doi.org/10.1182/blood.V122.21.5095.5095

Published: 2013

Journal Articles

Impaired Interaction Between Regulatory T Cells and Dendritic Cells in Immune Thrombocytopenia.

Lucia Catani, Daria Sollazzo, Antonio Curti, Sara Trabanelli, Francesca Palandri, Nicola Polverelli, Michele Baccarani, Nicola Vianelli, Roberto Lemoli

Blood (2009) 114 (22): 3511.

https://doi.org/10.1182/blood.V114.22.3511.3511

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial

CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.

The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.

Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Fludarabine, cytarabine and Idarubicin (FLAI-5) with or without Gemtuzumab Ozogamicin Is an Effective and Well Tolerated Regimen for Younger AML Patients: Real Life Data from a Single Center Register

Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation

Posaconazole for Primary Antifungal Prophylaxis in AML Patients: A Real Life Single Center Experience and a Comparison with the Historical Cohort

Combined Assessment of WT1 and BAALC Expression Levels Improves Risk Stratification in Myelodysplastic Syndromes

How We Treat Chronic Myeloid Leukemia Patients During Daily Practice? Case Studies From The Real Life Experience Of Two Genoa Centers Of Hematology

Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors

Efficacy and Tolerability Of Frontline Oral Fludarabine and Cyclophosphamide Combination Therapy For Elderly Patients With Chronic B-Cell Lymphocytic Leukaemia and Low Grade Non Hodgkin Lymphoma

Impaired Interaction Between Regulatory T Cells and Dendritic Cells in Immune Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only